DNLI Q4 2025 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$3M

Operating Income

-$137M

Net Income

-$129M

EPS (Diluted)

$-0.73

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$99M

Free Cash Flow

-$100M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$131M

Stockholders' Equity

$1.0B

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$3M	$0	—
Operating Income	-$137M	-$130M	-5.8%
Net Income	-$129M	-$115M	-12.0%